Great Bay Bio’s Board of Director Welcomes a New Member to Continuously Improve Its Management and Promote Its Core Stategy

Created on:2019-08-01 10:45

logo

August 1st,2019 Press Release

 

Great Bay Bio’s Board of Director Welcomes a New Member to Continuously Improve Its Management and Promote Its Core Stategy


[August 1st, 2019 – Hong Kong] Great Bay Bio, an AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) and biologics R&D welcomes a new member. On behalf of the board of director, Mr. Kingsley Leung, the chairman extends warm welcome to Mr. William Kung for his joining. Right now, Mr. Kung is the non-executive director of Great Bay Bio. At this critical moment for GBB to establish its core competitiveness, the joining of talents with different backgrounds will accelerate its development, steadily promote its progresses, and establish its long-term value.
        

Graduated from York University in Canada as the master of economics, Mr. Kung is currently an American Certified Public Accountant (AICPA: American Institute of Certified Public Accountant). Mr. Gong ever worked for Principal Global Investors in the United States for seven years, helping clients manage global assets of more than 9 billion US dollars. The clients included Sovereign Wealth Funds such as Singapore GIC. During his tenure at SouthWest Securities International Securities Ltd., he was responsible for the quantitative trading of financial products in Hong Kong and Chinese Mainland. In the past three consecutive years, the company has outperformed China's SOE index. Since June 2019, Mr. Kung has been responsible for the formation of investment funds in the Asset Management Department of Keungkong Group, and has led post-merger management of consumer goods and technology industries.

 

Regarding Mr. Kung’s joining, Mr. Kingsley Leung, chairman of the board of directors, said: "Mr. Kung’s financial background and relationship networks at home and abroad will certainly advance our financing plans of this year. Since its foundation, GBB has adhered to an international vision and aimed at the international market. We hope to effectively integrate the global capital market, biopharmaceutical industry and new technologies to solve prominent problems in drug development, such as inefficient R&D. Any technological improvements in drug R&D can significantly reduce our partners’ costs and lower the drug price to benefit the patients. With Mr. Kung’s joining, we can consider our development vision from a new perspective and achieve our goals through corporate governance and investor lock-in. An efficient governance structure is essential to attract new investors and strategic partners, which can be the key driver for GBB to generate value in a short time. This is what we urgently need. I would like to extend a warm welcome to Mr. Kung and look forward to working with him closely.

111

Mr. William Kung

 

Brief Introduction to Other Members of the GBB Board

Mr. Kingsley Leung, chairman of GBB’S Board of Director and Co-founder. Graduated from Imperial College London and Oxford University, he is a chartered financial analyst. Before the establishment of Great Bay Bio, he has been the chairman of the board of Hong Kong Uni-Bio Science Group Limited (690.HK). He has managed biomedical and financial companies for many years. Meanwhile, he successfully introduced a new generation of oncology, inflammation and respiratory medicine from multinational companies, and worked in several large investment banks and a family fund.

 

Dr. Chen Liang, CEO and Co-founder of Great Bay Bio, is the doctor of biochemistry from the University of Georgia and has 30-plus years of experience in biological R&D and project operation and management. He has worked as the senior executive in many well-known pharmaceutical companies in the United States and China. He has ever been responsible for the IND declaration of 5 biosimilar drugs and innovative macromolecule projects within three years and published more than 18 research papers or patent articles in international journals.

 

About Great Bay Bio 

 

Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.

GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.

GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.

The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.

 

 

For more details, please visit:www.greatbay-bio.com

Contact for business:js.chen@greatbay-bio.com

Contact for media and investment: public@greatbay-bio.com

Home    News    Great Bay Bio’s Board of Director Welcomes a New Member to Continuously Improve Its Management and Promote Its Core Stategy
PV:0
Collect